Compare REXR & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REXR | EXAS |
|---|---|---|
| Founded | 2013 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 11.0B |
| IPO Year | 2013 | N/A |
| Metric | REXR | EXAS |
|---|---|---|
| Price | $41.17 | $101.50 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 20 |
| Target Price | $43.10 | ★ $77.94 |
| AVG Volume (30 Days) | 2.2M | ★ 10.8M |
| Earning Date | 02-04-2026 | 11-03-2025 |
| Dividend Yield | ★ 4.17% | N/A |
| EPS Growth | ★ 15.85 | N/A |
| EPS | ★ 1.43 | N/A |
| Revenue | $997,931,000.00 | ★ $3,082,033,000.00 |
| Revenue This Year | $9.35 | $19.40 |
| Revenue Next Year | $3.81 | $13.51 |
| P/E Ratio | $28.97 | ★ N/A |
| Revenue Growth | 10.40 | ★ 14.47 |
| 52 Week Low | $29.68 | $38.81 |
| 52 Week High | $44.38 | $101.95 |
| Indicator | REXR | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 50.53 | 89.65 |
| Support Level | $39.53 | $100.95 |
| Resistance Level | $41.96 | $101.95 |
| Average True Range (ATR) | 0.76 | 0.34 |
| MACD | 0.05 | -1.01 |
| Stochastic Oscillator | 65.35 | 60.00 |
Rexford Industrial Realty Inc is a real estate investment trust engaged in owning, operating, and acquiring industrial properties in Southern California infill markets. The goal is to generate attractive risk-adjusted returns for stockholders by providing superior access to industrial property investments in Southern California infill markets. It has one operating segment business of investing in, operating, and repositioning/redeveloping industrial real estate properties located in Southern California infill markets.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.